Revelation Biosciences, Inc. (REVB)
Automate Your Wheel Strategy on REVB
With Tiblio's Option Bot, you can configure your own wheel strategy including REVB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol REVB
- Rev/Share 0.0102
- Book/Share 4.1599
- PB 0.3966
- Debt/Equity 0.0
- CurrentRatio 6.9196
- ROIC -0.7502
- MktCap 2443655.0
- FreeCF/Share -3.7934
- PFCF -0.2436
- PE -0.5369
- Debt/Assets 0.0
- DivYield 0
- ROE -1.4504
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026
Published: January 26, 2026 by: Accesswire
Sentiment: Neutral
SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will implement a 1-for-4 reverse split of its common stock. The reverse stock split will be effective as of the morning of January 28, 2026, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol "REVB.
Read More
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds
Published: January 23, 2026 by: Accesswire
Sentiment: Neutral
SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 13,065,000 shares of common stock, issued by the Company on September 11, 2025 (the "Existing Warrants"), at reduced exercise price of $0.86 per share. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to an effective registration statement on Form S-3 (File No.
Read More
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date
Published: October 29, 2025 by: Accesswire
Sentiment: Neutral
SAN DIEGO, CA / ACCESS Newswire / October 29, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the October 15, 2025 Special Meeting of Stockholders of Revelation Biosciences, Inc. (the "Company"), which was adjourned to October 29, 2025 has been canceled due to technical difficulty outside of the Company's control with stockholders being unable to vote all of their shares. The Company has decided to cancel the adjourned Special Meeting scheduled for today, October 29, at 12pm ET and to set a new record date of October …
Read More
About Revelation Biosciences, Inc. (REVB)
- IPO Date 2020-11-17
- Website https://www.revbiosciences.com
- Industry Biotechnology
- CEO James Rolke
- Employees 8